Leading the Way

Conventional RDS Treatment Strategies (Respiratory Distress Syndrome)
Conventional Treatment Strategies
INSURE Strategies (Intubation Surfactant Rapid Extubation)
Insure Strategies
Pharmacy Considerations
Pharmacy Considerations


CUROSURF® (poractant alfa) Intratracheal Suspension is the #1 surfactant used worldwide, and the number of infants treated continues to grow.

If you haven’t used CUROSURF in your NICU, you may be surprised to learn some interesting facts about how many NICUs in the US and worldwide have chosen CUROSURF as the surfactant of choice to treat infants with RDS.

  • More infants are treated with CUROSURF each year than with any other surfactant1,2
  • The number of hospitals using CUROSURF has more than quadrupled across the US since 20041
  • Over 20 years of clinical experience with more than 2.5 million infants treated3
4.5x increase in hospitals using CUROSURF in the US from 2004 to 2013

Ongoing research that keeps pace with clinical practice

  • Safety and efficacy established in 19 clinical trials, evaluating over 4700 patients3
  • Growing clinical portfolio of clinical literature that includes over 45 published articles3
  • The surfactant most widely studied for use with less invasive ventilation strategies3
  • Continuing support dedicated to the advancement of neonatology research and the treatment of RDS


Further reading